In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant body weight reduction in adults without diabetes and CagrisSema is a once weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising Weight Loss Efficacy of Cagrilintide and Semaglutide gutsandgrowth Efficacy and safety of co administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, CagriSema (CagrilintideSemaglutide) in Adults with Overweight or Obesity and Type 2 Diabetes Headlands Research Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine